Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II

In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantly better clinical and magnetic resonance imaging (MRI) outcomes than those receiving teriflunomide. To assess the efficacy and safety of ofatumumab versus teriflunomide in...

Celý popis

Podrobná bibliografie

Vydáno v:	Multiple sclerosis Ročník 28; číslo 10; s. 13524585221078825
Hlavní autoři:	Gärtner, Jutta, Hauser, Stephen L, Bar-Or, Amit, Montalban, Xavier, Cohen, Jeffrey A, Cross, Anne H, Deiva, Kumaran, Ganjgahi, Habib, Häring, Dieter A, Li, Bingbing, Pingili, Ratnakar, Ramanathan, Krishnan, Su, Wendy, Willi, Roman, Kieseier, Bernd, Kappos, Ludwig
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.09.2022
Témata:	Relapsing multiple sclerosis treatment-naive neurofilament light chain no evidence of disease activity progression independent of relapse activity recently diagnosed
ISSN:	1477-0970, 1477-0970
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!